Novavax, Inc.
NVAX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$10.22
▼ -1.16%
P/E
-6.72
Mkt Cap
$1.7B
52-Wk Range
$6.20–$11.97
52-Week Range
$6.20 - $11.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary nanoparticle vaccine platform technology enabling rapid vaccine development
- Strategic partnership with Takeda Pharmaceutical for global development and commercialization
- Diversified pipeline addressing multiple high-prevalence infectious diseases with significant market demand
- Advanced manufacturing capabilities supporting scalable vaccine production
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Mild headwinds expected
Regulatory approval and commercialization of NVX-CoV2373 COVID-19 vaccine
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+18.6% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NVAX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.32 vs -$0.38 consensus (+15.8% surprise). Revenue of $56.7M vs $52.5M expected (+8.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+15.8%
Revenue trend · last 8Q
—
-70%
+610%
-42%
-17%
+67%
-79%
-76%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$84.5M
$88.3M
$666.7M
$239.2M
$70.4M
$147.1M
$139.5M
$56.7M
Margins · last 8Q
Gross
74.9%
Operating
-96.8%
Profit
-94.2%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: TD Cowen · May 6, 2026
vs Industry
How NVAX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related